Tumor lysis syndrome induced by fludarabine monophosphate: a case report.
Nakhoul
F
F
Green
J
J
Abassi
Z A
ZA
Carter
A
A
D058186:Acute Kidney Injury / Q000209:etiology / Q000517:prevention & control; D000493:Allopurinol / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D007970:Leukopenia / Q000209:etiology; D008875:Middle Aged; D017693:Sodium Bicarbonate / Q000627:therapeutic use; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000517:prevention & control; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate; D000493:Allopurinol; D017693:Sodium Bicarbonate